Gilead Sciences, Inc. bought $20M of KYTX
owner at Kyverna Therapeutics, Inc.. 910,000 shares at an average of $22.00, traded Feb 12, 2024, filed Feb 13, 2024.
Score components
- +12Role10% owner
- +25Trade size$20.0M at market
- +6Relative to holdingsHoldings up 28%
- +10Price context0% above the 52-week low
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- -5Track recordMedian 6-month excess return -7% over 3 past buys
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.6%, 3m -47.8%, 6m -76.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-24-003026, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 12, 2024 | CConversion Common Stock | +3,216,119 | - | - | 3,216,119 | Feb 13, 2024 |
| Feb 12, 2024 | POpen-market purchase Common Stock | +910,000 | $22.00 | $20M | 4,126,119 | Feb 13, 2024 |
| Feb 12, 2024 | CConversion Series A-2 Convertible Preferred Stockderivative | -6,890,744 | $0.00 | $0 | 0 | Feb 13, 2024 |
| Feb 12, 2024 | CConversion Series B Convertible Preferred Stockderivative | -7,746,139 | $0.00 | $0 | 0 | Feb 13, 2024 |
Related signals
Other insiders at Kyverna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Kyverna Therapeutics, Inc. | Westlake BioPartners Opportunity Fund I, L.P. owner | $1000k 133,333 shares | +18% | |
| 51Moderate | Kyverna Therapeutics, Inc. | Beth C Seidenberg director | $1000k 133,333 shares | +18% | |
| 14Weak | Kyverna Therapeutics, Inc. | Karen Marie Walker Chief Technology Officer | $293k 23,998 shares | -51% | |
| 60Notable | Kyverna Therapeutics, Inc. | Bain Capital Life Sciences Investors, LLC owner | $9.9M 450,000 shares | +17% | |
| 65Notable | Kyverna Therapeutics, Inc. | Vida Ventures, LLC owner | $5.6M 253,136 shares | - | |
| 66Notable | Kyverna Therapeutics, Inc. | Northpond Ventures III GP, LLC other | $9.9M 450,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.